Literature DB >> 22208965

Local failure in resected N1 lung cancer: implications for adjuvant therapy.

Kristin A Higgins1, Junzo P Chino, Mark Berry, Neal Ready, Jessamy Boyd, David S Yoo, Chris R Kelsey.   

Abstract

PURPOSE: To evaluate actuarial rates of local failure in patients with pathologic N1 non-small-cell lung cancer and to identify clinical and pathologic factors associated with an increased risk of local failure after resection. METHODS AND MATERIALS: All patients who underwent surgery for non-small-cell lung cancer with pathologically confirmed N1 disease at Duke University Medical Center from 1995-2008 were identified. Patients receiving any preoperative therapy or postoperative radiotherapy or with positive surgical margins were excluded. Local failure was defined as disease recurrence within the ipsilateral hilum, mediastinum, or bronchial stump/staple line. Actuarial rates of local failure were calculated with the Kaplan-Meier method. A Cox multivariate analysis was used to identify factors independently associated with a higher risk of local recurrence.
RESULTS: Among 1,559 patients who underwent surgery during the time interval, 198 met the inclusion criteria. Of these patients, 50 (25%) received adjuvant chemotherapy. Actuarial (5-year) rates of local failure, distant failure, and overall survival were 40%, 55%, and 33%, respectively. On multivariate analysis, factors associated with an increased risk of local failure included a video-assisted thoracoscopic surgery approach (hazard ratio [HR], 2.5; p = 0.01), visceral pleural invasion (HR, 2.1; p = 0.04), and increasing number of positive N1 lymph nodes (HR, 1.3 per involved lymph node; p = 0.02). Chemotherapy was associated with a trend toward decreased risk of local failure that was not statistically significant (HR, 0.61; p = 0.2).
CONCLUSIONS: Actuarial rates of local failure in pN1 disease are high. Further investigation of conformal postoperative radiotherapy may be warranted.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22208965     DOI: 10.1016/j.ijrobp.2011.07.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.

Authors:  Yujin Xu; Jianqiang Li; Jin Wang; Xiao Hu; Honglian Ma; Pu Li; Xiao Zheng; Ming Chen
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

2.  Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.

Authors:  Paolo Borghetti; Fernando Barbera; Marco Lorenzo Bonù; Francesca Trevisan; Stefano Ciccarelli; Paola Vitali; Marta Maddalo; Luca Triggiani; Nadia Pasinetti; Sara Pedretti; Bartolomea Bonetti; Gianluca Pariscenti; Andrea Tironi; Alberto Caprioli; Michela Buglione; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2016-05-26       Impact factor: 3.469

Review 3.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

4.  Effect of postradiotherapy neck dissection on nonregional disease sites.

Authors:  Mark C Ranck; Rainier Abundo; Gina Jefferson; Antonia Kolokythas; Barry L Wenig; Ralph R Weichselbaum; Michael T Spiotto
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-01       Impact factor: 6.223

Review 5.  Adjuvant treatment in lung cancer.

Authors:  Begoña Taboada Valladares; Patricia Calvo Crespo; Urbano Anido Herranz; Antonio Gómez Caamaño
Journal:  J Clin Transl Res       Date:  2021-04-16

6.  The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.

Authors:  Wen Feng; Qin Zhang; Xiao-Long Fu; Xu-Wei Cai; Zheng-Fei Zhu; Huan-Jun Yang; Jia-Qing Xiang; Ya-Wei Zhang; Hai-Quan Chen
Journal:  BMC Cancer       Date:  2015-05-02       Impact factor: 4.430

7.  Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis.

Authors:  Ying Zhu; Lei Fu; Wang Jing; Li Kong; Jinming Yu
Journal:  Cancer Manag Res       Date:  2019-12-31       Impact factor: 3.989

8.  Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy.

Authors:  Chengcheng Fan; Shugeng Gao; Zhouguang Hui; Jun Liang; Jima Lv; Xiaozhen Wang; Jie He; Luhua Wang
Journal:  Radiat Oncol       Date:  2013-12-09       Impact factor: 3.481

9.  Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.

Authors:  Wen Feng; Yuan Li; Lei Shen; Xu-Wei Cai; Zheng-Fei Zhu; Jian-Hua Chang; Jia-Qing Xiang; Ya-Wei Zhang; Hai-Quan Chen; Xiao-Long Fu
Journal:  Oncotarget       Date:  2016-02-09

10.  Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.

Authors:  Jamie E Chaft; Patrick M Forde; Joshua E Reuss; Valsamo Anagnostou; Tricia R Cottrell; Kellie N Smith; Franco Verde; Marianna Zahurak; Mara Lanis; Joseph C Murray; Hok Yee Chan; Caroline McCarthy; Daphne Wang; James R White; Stephen Yang; Richard Battafarano; Stephen Broderick; Errol Bush; Malcolm Brock; Jinny Ha; David Jones; Taha Merghoub; Janis Taube; Victor E Velculescu; Gary Rosner; Peter Illei; Drew M Pardoll; Suzanne Topalian; Jarushka Naidoo; Ben Levy; Matthew Hellmann; Julie R Brahmer
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.